



FEP Medical Policy Manual

FEP 1.03.05 Patient-Controlled End of Range Motion Stretching Devices

Effective Policy Date: July 1, 2019

Related Policies:

None

Original Policy Date: March 2015

Patient-Controlled End of Range Motion Stretching Devices

Description

Patient-controlled stretching devices are used at home to increase range of motion (ROM) in patients who have impaired functional status due to decreased ROM. We address two types of commercially available devices. Static progressive stretch (SPS) devices (eg, JAS, Static-Pro) provide low- to moderate-intensity stretching with a crank or ratchet that progressively increases the stretch within each session, and serial stretch devices (eg, ERMI) use hydraulics to alternate between periods of higher intensity stretch and relaxation.

OBJECTIVE

The objective of this evidence review is to evaluate whether patient-controlled stretching devices (static or serial) improve health outcomes in patients with a decreased range of motion.

POLICY STATEMENT

Patient-controlled end range of motion stretching devices are considered **investigational**.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

The U.S. Food and Drug Administration has determined that devices classified as "Exerciser, Non-Measuring" are considered class I devices and exempt from 510(k) requirements. This classification does not require submission of clinical data on efficacy, only notification to the Food and Drug Administration prior to marketing. Food and Drug Administration product code: ION.

RATIONALE

Summary of Evidence

For individuals who have functional limitations in ROM who receive SPS devices and physical therapy, the evidence includes RCTs, a systematic review, and case series. Therelevant outcomes include symptoms, change in disease status, functional outcomes, and QOL. Three RCTs have evaluated SPS devices but comparators in each differed (physical therapy, a dynamic splint, and a serial stretch device). One RCT reported significant improvements in Disabilities of the Arm Shoulder and Hand questionnaire scores and shoulder ROM compared with physical therapy alone at the end of four4 weeks of treatment, with significant improvements maintained at the two-year follow-up. A second RCT evaluating SPS in the elbow found similar improvements in most ROM outcomes compared with dynamic splinting, except better Disabilities of the Arm Shoulder and Hand scores in the SPS group at 6 months and better flexion contracture in the dynamic splinting group at 12 months. A third RCT, which compared SPS with serial stretch devices, found greater improvements in WOMAC and knee flexion scores with the serial stretch devices. A systematic review and meta-analysis of case reports and series found that similar clinical efficacy for increasing elbow ROM and flexion can be achieved using dynamic splints, SPS devices, and static braces. It is not known whether patient compliance is higher with SPS devices because results have indicated these devices improve ROM faster than comparators. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have functional limitations in ROM who receive serial stretch devices and physical therapy, the evidence includes an RCT and observational studies. Therelevant outcomes include symptoms, change in disease status, functional outcomes, and QOL. The best evidence consists of serial stretching with ERMI devices used to treat knee ROM. One small RCT and a larger retrospective comparative study have reported that high-intensity stretching with ERMI devices improved ROM more than lower intensity stretching devices in patients who were post injury or surgery. Other available data consist of retrospective case series that have demonstrated improved ROM in patients whose ROM had plateaued with physical therapy. The clinical significance of gains in this surrogate outcome measure is unclear. Further high-quality comparative trials are needed to determine whether these patient-controlled devices improve functional outcomes better than alternative treatments and identify the patient populations that might benefit. The evidence is insufficient to determine the effects of the technology on health outcomes.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

No guidelines or statements were identified.

U.S. Preventive Services Task Force Recommendations

Not applicable.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Stephenson JJ, Quimbo RA, Gu T. Knee-attributable medical costs and risk of re-surgery among patients utilizing non-surgical treatment options for knee arthrofibrosis in a managed care population. *Curr Med Res Opin.* May 2010;26(5):1109-1118. PMID 20225995.
2. Rowe PJ, Myles CM, Walker C, et al. Knee joint kinematics in gait and other functional activities measured using flexible electrogoniometry: how much knee motion is sufficient for normal daily life? *Gait Posture.* Oct 2000;12(2):143-155. PMID 10998612.
3. Shelbourne KD, Gray T. Minimum 10-year results after anterior cruciate ligament reconstruction: how the loss of normal knee motion compounds other factors related to the development of osteoarthritis after surgery. *Am J Sports Med.* Mar 2009;37(3):471-480. PMID 19059893.
4. International Knee Documentation Committee (IKDC). IKDC: Knee Form. 2000; <http://www.aaos.org/uploadedFiles/PreProduction/Quality/Measures/IKDCEnglishUS.pdf>. Accessed February 8, 2018.
5. Pappotto BA, Mills T. Treatment of severe flexion deficits following total knee arthroplasty: a randomized clinical trial. *Orthop Nurs.* Jan-Feb 2012;31(1):29-34. PMID 22278649.
6. Bonutti PM, McGrath MS, Ulrich SD, et al. Static progressive stretch for the treatment of knee stiffness. *Knee.* Aug 2008;15(4):272-276. PMID 18538574.
7. Ibrahim MI, Johnson AJ, Pivec R, et al. Treatment of adhesive capsulitis of the shoulder with a static progressive stretch device: a prospective, randomized study. *J Long Term Eff Med Implants.* Jan 2012;22(4):281-291. PMID 23662659.
8. Ibrahim M, Donatelli R, Hellman M, et al. Efficacy of a static progressive stretch device as an adjunct to physical therapy in treating adhesive capsulitis of the shoulder: a prospective, randomised study. *Physiotherapy.* Sep 2014;100(3):228-234. PMID 24211154.
9. Hussein AZ, Ibrahim MI, Hellman MA, et al. Static progressive stretch is effective in treating shoulder adhesive capsulitis: Prospective, randomized, controlled study with a two-year follow-up. *Eur J Physiother.* Jun 24 2015;17(3):138-147.
10. Lindenhovius AL, Doornberg JN, Brouwer KM, et al. A prospective randomized controlled trial of dynamic versus static progressive elbow splinting for posttraumatic elbow stiffness. *J Bone Joint Surg Am.* Apr 18 2012;94(8):694-700. PMID 22517385.
11. Ulrich SD, Bonutti PM, Seyler TM, et al. Restoring range of motion via stress relaxation and static progressive stretch in posttraumatic elbow contractures. *J Shoulder Elbow Surg.* Mar 2010;19(2):196-201. PMID 19959379.
12. Muller AM, Sadoghi P, Lucas R, et al. Effectiveness of bracing in the treatment of nonosseous restriction of elbow mobility: a systematic review and meta-analysis of 13 studies. *J Shoulder Elbow Surg.* Aug 2013;22(8):1146-1152. PMID 23796383.
13. McGrath MS, Ulrich SD, Bonutti PM, et al. Static progressive splinting for restoration of rotational motion of the forearm. *J Hand Ther.* Jan-Mar 2009;22(1):3-8; quiz 9. PMID 18950990.
14. McGrath MS, Ulrich SD, Bonutti PM, et al. Evaluation of static progressive stretch for the treatment of wrist stiffness. *J Hand Surg Am.* Nov 2008;33(9):1498-1504. PMID 18984330.
15. Lucado AM, Li Z, Russell GB, et al. Changes in impairment and function after static progressive splinting for stiffness after distal radius fracture. *J Hand Ther.* Oct-Dec 2008;21(4):319-325. PMID 19006757.
16. Branch TP, Karsch RE, Mills TJ, et al. Mechanical therapy for loss of knee flexion. *Am J Orthop (Belle Mead NJ).* Apr 2003;32(4):195-200. PMID 12723771.
17. Dempsey AL, Mills T, Karsch RM, et al. Maximizing total end range time is safe and effective for the conservative treatment of frozen shoulder patients. *Am J Phys Med Rehabil.* Sep 2011;90(9):738-745. PMID 21430510.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
March 2015	New policy	
December 2016	Replace policy	Policy updated with literature review through June 13, 2016; references 7-9 and 11-12 added. Policy title changed to "Patient-Controlled End Range of Motion Stretching Devices".
March 2018	Replace policy	Policy updated with literature review through January 8, 2018; no references added. Policy statement unchanged.
June 2019	Replace policy	Policy updated with literature review through January 9, 2019; no references added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.